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Retinoic acid receptor-related orphan nuclear receptor alpha (ROR␣) is a potent tumor suppressor that reduces cell proliferation and inhibits tumor growth. However, the molecular mechanism by which it inhibits cell proliferation remains unknown. We demonstrate a noncanonical nuclear receptor pathway in which ROR␣ binds to E2F1 to inhibit cell cycle progression. We showed that ROR␣ bound to the heptad repeat and marked box region of E2F1 and suppressed E2F1-regulated transcription in epithelial cells. Binding of ROR␣ inhibited E2F1 acetylation and its DNA-binding activity by recruiting histone deacetylase 1 (HDAC1) to the protein complexes. Knockdown of HDAC1 or inhibition of HDAC activity at least partially rescued transcription factor activity of E2F1 that was repressed by ROR␣. Importantly, ROR␣ levels were increased in mammary ducts compared to terminal end buds and inversely correlated with expression of E2F1 target genes and cell proliferation. Silencing ROR␣ in mammary epithelial cells significantly enhanced cell proliferation in the ductal epithelial cells and promoted side branching of the mammary ducts. These results reveal a novel link between ROR␣ and E2F1 in regulating cell cycle progression and mammary tissue morphogenesis. N uclear receptors, a family of ligand-dependent transcription factors, regulate gene expression by directly binding to the cis response elements in the regulatory regions (1, 2) . Retinoic acid receptor-related orphan nuclear receptor alpha (ROR␣) is an orphan nuclear receptor and plays critical roles in many physiological processes, including cell differentiation, metabolism, inflammation, transformation, and circadian rhythm (3) (4) (5) (6) (7) (8) (9) (10) (11) . The canonical way that ROR␣ regulates gene expression is through ROR response elements in the regulatory regions of the target genes (12, 13) . ROR␣ recruits a number of transcriptional coactivators and corepressors to the target genes, including steroid receptor coactivator 1 (14) and p300 (15) , nuclear receptor corepressor, and silencing mediator for retinoic acid and thyroid hormone receptors (16) . These transcriptional cofactors modulate the chromatin structure to induce or repress transcription. Unlike the canonical pathway of nuclear receptor to regulate gene expression, a number of recent studies show that ROR␣ acts as a transcriptional cofactor, binding to ␤-catenin or p53 to regulate target gene expression or modulate protein stability (7, 17) .
Spatial and temporal regulation of cell proliferation is crucial for normal tissue development and maintenance of the differentiated state (18) . For instance, mammary epithelial cells in the mature ducts remain growth arrested, while cells in terminal end buds are highly proliferative (19, 20) . The different cell proliferation status in terminal end buds and ducts is important for mammary gland branching morphogenesis and maintenance of the ductal structure (21, 22) . Enhancing cell proliferation in mammary epithelial cells in the long run is sufficient to induce tumorigenesis (23, 24) . We and others have shown that ROR␣ expression is significantly downregulated during tumor development and progression (7, 25) , and exogenous ROR␣ reduces cell proliferation and inhibits tumor growth. But the molecular mechanism by which ROR␣ inhibits cell proliferation remains to be determined.
Cell proliferation is controlled by a series of cell cycle regulators, such as transcription factor E2Fs, cyclin E, cyclin-dependent kinases, and cell cycle brakes pRB and p27 (26) (27) (28) (29) (30) (31) . E2F1 is a member of the E2F transcription factor family and plays important roles in regulating G 1 /S transition, DNA synthesis, and apoptosis (32) (33) (34) (35) . E2F1 activity is regulated by a number of proteins through protein-protein interaction (36) (37) (38) . For example, binding of pRb inhibits E2F1 activity at G 1 phase, and phosphorylation of pRB releases it from E2F1 and leads to E2F1 activation (39) . E2F1 activity is also regulated by a number of covalent modifications, such as acetylation and phosphorylation (40, 41) . Acetylation of lysine residues 117, 120, and 125 by the acetyltransferase complex CBP/p/CAF enhances E2F1 DNA binding ability and stabilizes E2F1 (41) .
Using gene expression profile analysis, we showed that transcription of E2F1 target genes was suppressed by ROR␣. Coimmunoprecipitation (co-IP) and in vitro binding data demonstrated that ROR␣ bound to E2F1 and enhanced the interaction between E2F1 and histone deacetylase 1 (HDAC1), which, in turn, reduced E2F1 acetylation and inhibited its DNA-binding activity. Importantly, high levels of ROR␣ were associated with reduced cell proliferation and repression of E2F1 target genes during mammary branch morphogenesis. Silencing ROR␣ in the mammary epithelial cells enhanced cell proliferation in the ductal epithelial cells and promoted side branching. These results identified a noncanonical pathway of ROR␣ to regulate gene expression and mammary gland development, in which ROR␣ binds to E2F1 to inhibit E2F1-dependent cell cycle progression.
MATERIALS AND METHODS
Antibodies and reagents. The 5-ethynyl-2=-deoxyuridine (EdU) staining kit was from Invitrogen. Matrigel (laminin-rich extracellular matrix [lrECM] ) and type I collagen were from BD Bioscience. ROR␣ cDNA was purchased from Open Biosystems. E2F1 and DP1 cDNA clones were purchased from Addgene. E2F1-Luc luciferase reporter vector was purchased from Signosis, Inc. Plasmids carrying short hairpin RNA (shRNA) against ROR␣ (shROR␣ plasmids) and shHDAC1 plasmids (a kind gift from Zhou P. Binhua) were purchased from Sigma. HDAC inhibitor trichostatin A (TSA) was purchased from Sigma. Antibodies against the following antibodies were obtained: ROR␣, E2F1, and lamin A/C (Santa Cruz); Flag (Sigma); Ki67 (Vector Laboratories); acetyllysine (Millipore); and HDAC1 (Affinity BioReagents).
Cell culture and virus preparation. HMT-3522 S1 cells (hereafter referred to as S1 cells; a kind gift from Mina J. Bissell) were maintained in Dulbecco modified Eagle medium (DMEM)-F-12 medium containing insulin at 2.5 ϫ 10 Ϫ7 g/ml, transferrin at 1.0 ϫ 10 Ϫ5 g/ml, sodium selenite at 2.6 ϫ 10 Ϫ9 g/ml, 1.0 ϫ 10 Ϫ10 M estradiol, 1.4 ϫ 10 Ϫ6 M hydrocortisone, prolactin at 5.0 ϫ 10 Ϫ6 g/ml, and epidermal growth factor (EGF) at 1.0 ϫ 10 Ϫ8 ng/ml. MDA-MB 231 cells (ATCC) were propagated in DMEM-F-12 (Sigma) with 10% fetal bovine serum (Invitrogen). Flag-tagged ROR␣ cDNA was cloned into plasmid pCDH1 and generated expression vector pCDH1-ROR〈l-Flag. HEK293 FT cells were transfected with pCDH1 or shRNA vector (Sigma) plus packaging lentivector using Lipofectamine (Invitrogen). Cancer cells were infected with lentivirus and selected by puromycin 48 h after infection.
Microarray analysis. Control and ROR␣-expressing MDA-MB 231 and MDA-MB 157 cells were isolated from 3D cultures with phosphatebuffered saline (PBS)-EDTA (5 mM EDTA, 1 mM NaVO 4 , 1.5 mM NaF in PBS) on ice as previously described (42) . Purified total cellular RNA was extracted using an RNeasy minikit with on-column DNase digestion (Qiagen). RNA was quantified by measuring optical density at 260 nm, and quality was verified by agarose gel electrophoresis. Affymetrix microarray analysis was performed using the Affymetrix HuGene-1.0 highthroughput array (HTA) GeneChip system. Preprocessing, normalization, and filtering were performed using R Bioconductor (43) . Gene set enrichment analysis was performed with GSEA v2.07 (http://www .broadinstitute.org/gsea/index.jsp) (44) . E2F1 target gene expression levels in terminal end buds and mammary ducts were derived from a published microarray data set (Gene Expression Omnibus accession number GSE2988). Unsupervised hierarchical clustering analysis was performed with Cluster (uncentered correlation, average linkage), and results were visualized with TreeView (http://www.eisenlab.org/eisen/?page_idϭ42).
Luciferase reporter assay. A luciferase reporter vector containing four E2F response elements (TTTCGCGC) was purchased from Signosis. MDA-MB 231 cells were transfected with pCDNA plus pE2F1-Luc luciferase vector (1:5) . A luciferase vector pE2F1-Luc stable expression cell clone was selected by G418 (8.0 ϫ 10 Ϫ4 g/ml) treatment. Cell lysates were collected for the luciferase assay 48 h after infection with pCDH1-ROR〈l-Flag.
Immunohistochemistry. Mouse mammary gland sections and xenograft tumor sections were deparaffinized and hydrated from xylene, 100% ethanol, 95% ethanol, 85% ethanol, and 70% ethanol to PBS solution. Endogenous peroxidase was blocked by incubation with 3% H 2 O 2 for 20 min. At the antigen retrieval step, slides were steamed in citrate sodium buffer for 30 min. Slides were incubated with antibodies at 4°C overnight, and then the sections were incubated with goat anti-rabbit IgG conjugated with horseradish peroxidase at room temperature for 60 min. After diaminobenzidine (DAB) staining, images were taken by Nikon and scored blindly.
RT-PCR. Total RNA was extracted from cells using TRIzol reagent (Invitrogen). cDNA was synthesized using the SuperScript First Strand Synthesis kit (Invitrogen) from 0.5-to 1.0-g RNA samples. cDNA synthesis was performed with the SuperScript III First-Strand Synthesis System according to the manufacturer's instructions. Quantitative reverse transcription-PCRs (RT-PCRs) were carried out using SYBR green PCR master mix reagents on an ABI 7500 Fast real-time PCR system (Applied Biosystems). Thermal cycling was conducted at 95°C for 30 s, followed by 40 cycles of amplification at 95°C for 5 s, 55°C for 30 s, and 72°C for 15 s. The relative quantification of gene expression for each sample was analyzed by the threshold cycle (C T ) method. The following primers were used for amplification: for CDC6, 5=-TGGGCGATGACAACCTATGC-3= and 5=-TGGCTAGTTCTCTTTTGCTAGGA-3=; for ESPL1, 5=-CCGCCT TGAAGGAGTTCCTG-3= and 5=-GGGGTAGACACTAAGTAGCCAT-3=; for MCM4, 5=-GACGTAGAGGCGAGGATTCC-3= and 5=-GAGTGC CGTATGTCAGTGGT-3=; for POLE2, 5=-GAATGCAGTCAGTCTGTTG ATGA-3= and 5=-AACCTATCACCGGAGGAGTAAAT-3=; and for 18S rRNA, 5=-ACCTGGTTGATCCTGCCAGT-3= and 5=-CTGACCGGGTT GGTTTTGAT-3=.
Coimmunoprecipitation assay. Cells were lysed with 400 l of icecold hypotonic gentle lysis buffer (10 mM Tris-HCl [pH 7.5], 10 mM NaCl, 2 mM EDTA, 0.5% Triton X-100, 1ϫ protease inhibitor cocktail set I [Calbiochem]) and incubated on ice for 10 min. After sonication, the protein complexes were pulled down with anti-Flag M2 affinity gel (Sigma), monoclonal antihemagglutinin (anti-HA)-agarose (Sigma), or anti-E2F antibody (Santa Cruz).
ChIP assay. Vector control and ROR␣-expressing MDA-MB 231 cells were cross-linked using formaldehyde for the chromatin immunoprecipitation (ChIP) assay. The ChIP assay was performed based on the Upstate Biotechnology ChIP protocol, with a few modifications. After formaldehyde cross-linking, nuclei were isolated with a nuclear isolation kit (Sigma) and resuspended in ChIP lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl [pH 8.0]) containing protease inhibitor cocktail. Protein-DNA complexes were immunoprecipitated as per the Upstate protocol. Isolated DNA was then analyzed by RT-PCR using the following primers: CDC6 promoter, 5=-ACTACAGCCAATCAGAAT CGAGGC-3= and 5=-TCCTCTTCTTTCCACCTCCTCAGT-3=, and POLE2 promoter, 5=-GGAGACCAAGCAGGGATCTT-3= and 5=-GCA ACTTGAAGGCGGAGAG-3=.
GST pulldown assay. Full-length E2F1 gene and deletion mutants (M1 to M5) were cloned into pGEX-4T-1 plasmid. Full-length ROR␣1, the DBD (containing the DNA-binding domain and hinge domain), or ligand-binding domain (LBD) was cloned into the pGEX-4T-1 plasmid. Glutathione S-transferase (GST) fusion protein expression was induced in Escherichia coli by 0.1 mM isopropyl-␤-D-thiogalactopyranoside (IPTG) at 19°C overnight. Bacteria were lysed in radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris, 150 mM NaCl, 0.5% sodium deoxycholate, 1% NP-40) with protease inhibitors and purified using Pierce glutathione-agarose (Thermo Scientific). Purified GST-fused proteins were confirmed by Coomassie staining. HEK293 FT cells were transfected with pCDH1-ROR␣1-flag or pCDH1-E2F1-flag plasmid using FuGENE HD transfection reagent (Promega). Cells were lysed in RIPA buffer with protease inhibitors 36 h after transfection. For the pulldown assay, GSTfused protein binding beads incubated with HEK293 FT cells at 4°C for 4 h and then washed with RIPA buffer three times for immunoblotting analysis.
Flow cytometry analysis. Vector control and ROR␣-expressing MDA-MB 231 cells were starved with serum for 24 h and then trypsinized for flow cytometry analysis. shROR␣-expressing and vector control HMT-3522 S1 cells were trypsinized for flow cytometry analysis after starvation with EGF for 24 h. Cells were washed with 5 ml of ice-cold PBS, suspended in 500 l of PBS, and then immediately fixed with 5 ml of cold 70% ethyl alcohol (EtOH). Fixed cells were incubated with 200 l of propidium iodide solution (0.2 mg/ml) and 20 l of RNase (10 mg/ml) at 37°C for 45 min. Flow cytometry analysis was performed at the fluorescence-activated cell sorting (FACS) facility at the School of Medicine, University of Kentucky.
Mammary fat pad clearance and mammary epithelium cell transplantation. Primary mammary organoids were isolated from 6-to 7-week-old female FVB mice (Friend virus B-outbred colony of Swiss mice) with collagenase-trypsin solution (0.2% trypsin, 0.2% collagenase type IV, 5% fetal calf serum, 5 g/ml of insulin, and 50 g/ml of gentamicin in 50 ml of DMEM-F-12) as previously described (45) . The isolated mammary organoids were infected with lentivirus containing shControl or shROR␣ before transplantation. Three-week-old female FVB mice were anesthetized, and the inguinal fat pads were cleared by surgically removing the developing mammary epithelium. A small pocket was formed in the cleared fat pad and shControl-infected mammary organoids were placed in the pocket; shROR␣-infected mammary organoids were transplanted on the contralateral side using the same procedure. Five weeks after surgery, the outgrowth of transplants was analyzed by performing whole mounts.
Whole-mount staining of mammary glands. The fourth mammary glands were freshly dissected, spread on a glass slide, and fixed in Carnoy's fixative (6 parts ethanol, 3 parts chloroform, and 1 part glacial acetic acid) overnight. After being washed in 70% ethanol for 15 min, glands were rinsed in distilled water for 5 min and then stained in carmine alum stain solution (0.2% [wt/vol] carmine, 0.5% [wt/vol] aluminum potassium sulfate) for several hours to overnight. Slides were washed with 70% ethanol, followed by 95% and 100% ethanol. For long-term storage and photographic documentation, glands were cleared in xylene and mounted with Cytoseal 60 (Thermo Scientific) mounting medium. Whole mounts were photographed using a Nikon microscope.
Statistical analysis. Experiments were repeated at least three times. Results were reported as means Ϯ standard errors of the means (SEM); significance of difference was assessed by an independent Student t test. A P value of Ͻ0.05 represented statistical significance, and a P value of Ͻ0.01 represented high statistical significance.
RESULTS
ROR␣ inhibits cell proliferation and expression of the E2F1 target genes. We showed previously that downregulation of ROR␣ in breast cancer is associated with enhanced cell proliferation and aggressive phenotypes of breast cancer cells in 3D culture (25) . Expression of ROR␣ in T4-2 cells inhibits tumor growth, suggesting that ROR␣ may modulate cell proliferation (25) . Introducing exogenous ROR␣ in breast cancer cell lines MDA-MB 157 and MDA-MB 231 (Fig. 1A) significantly inhibited cell proliferation in 3D culture (Fig. 1B) . Ki67 staining showed that expression of ROR␣ also inhibited tumor growth and suppressed proliferation of breast cancer cells in vivo (Fig. 1C and D) .
To understand how ROR␣ inhibits cell proliferation, we performed microarray analysis in control and ROR␣-expressing breast cancer cells. Hundreds of genes were identified to be differentially expressed between the control and the ROR␣-expressing cells. Interestingly, most of these genes do not contain ROR response elements in their regulatory regions, suggesting that ROR␣ modulates their expression indirectly. Using gene set enrichment analysis (GSEA), we found that genes related to the KEGG cell cycle pathway (Fig. 1E) and E2F1-targeted genes were downregulated in ROR␣-expressing breast cancer cells (Fig. 1F and G) . Flow cytometry analysis showed that ectopic expression of ROR␣ in MDA-MB 231 cells significantly increased the number of cells at G 0 /G 1 phase and reduced the number of cells in S phase (Fig. 1H) . Silencing ROR␣ in nonmalignant S1 cells inhibited cell proliferation (Fig. 1I) and reduced the percentage of cells in G 1 phase (P Ͻ 0.05), while the number of cells in S phase and G 2 phase was significantly increased in ROR␣-silenced cells compared to control cells (P Ͻ 0.05) (Fig. 1J) . These results suggest that ROR␣ inhibits cell proliferation by inducing G 1 /S arrest in mammary epithelial cells.
To confirm that ROR␣ inhibits E2F1-targeted genes, a couple of genes that regulate cell cycle progression and DNA replication were analyzed by RT-PCR. The results showed that mRNA levels of CDC6 (P Ͻ 0.01), ESPL1 (P Ͻ 0.01), MCM4 (P Ͻ 0.01), and POLE2 (P Ͻ 0.01) were significantly downregulated in ROR␣-expressing MDA-MB 231 cells compared with control cells (P Ͻ 0.01) (Fig. 2A) . Similar results were also observed with MDA-MB 157 cells (Fig. 2A) . Silencing ROR␣ in S1 cells enhanced the expression of CDC6 (P Ͻ 0.01), MCM4 (P Ͻ 0.01), and POLE2 (P Ͻ 0.05) (Fig. 2B) . Eln, a gene that is not regulated by E2F1, was used 
01). (B) Real-time RT-PCR results
showed that mRNA levels of CDC6, ESPL1, MCM4, and POLE2 were upregulated in ROR␣ knockdown S1 cells compared with shRNA control S1 cells (n ϭ 4; *, P Ͻ 0.05; **, P Ͻ 0.01). (C) Luciferase analysis was performed for MDA-MB 231 cells that were stably transfected with control (ctrl-Luc) or E2F1 response luciferase reporter vector (E2F1-Luc). ROR␣ inhibited E2F1-driven reporter activity (n ϭ 3; **, P Ͻ 0.
01). (D) E2F1 protein levels in control and ROR␣-expressing MDA-MB 231 cells were examined by Western blotting. (E and F) Chromatin immunoprecipitation results showed that overexpression of ROR␣ significantly inhibited binding of E2F1 to the promoter regions of CDC6 (E) and POLE2 (F)
. Levels of AcH3 and AcH4 in the promoter regions of CDC6 and POLE2 were also reduced in ROR␣-expressing cells (n ϭ 3; *, P Ͻ 0.05; **, P Ͻ 0.01). The ChIP data were normalized to input DNA, and the results represent the relative changes in ROR␣ group compared to the control group.
as a negative control in real-time RT-PCR (data not shown). To examine whether ROR␣ directly regulates E2F1 transcriptional activity, luciferase assays were performed with MDA-MB 231 cells that were stably transfected with the E2F1 response report vector (E2F1-Luc). Introducing exogenous ROR␣ significantly inhibited the luciferase activity driven by E2F1 (P Ͻ 0.01) (Fig. 2C) . These results indicate that ROR␣ suppressed E2F1-regulated transcription.
We found that ROR␣ expression had little effect on E2F1 protein levels in MDA-MB 231 cells (Fig. 2D) . To understand how ROR␣ inhibits E2F1 activity, we performed chromatin immunoprecipitation experiments. The E2F1-chromatin complexes were pulled down with anti-E2F1 antibody from the control and ROR␣-expressing MDA-MB 231 cells. Enrichment of specific DNA fragments was measured by quantitative PCR. Ectopic expression of ROR␣ significantly inhibited binding of E2F1 to the promoter regions of CDC6 (P Ͻ 0.01) and POLE2 (P Ͻ 0.05) (Fig. 2E and F) . Levels of acetylated histone H3 (AcH3) and H4 (AcH4) in the promoter regions of CDC6 and POLE2 were also significantly reduced upon ROR␣ expression (Fig. 2E and F) . Thus, ROR␣ inhibits binding of E2F1 to the targeted genes and suppresses E2F1-induced chromatin remodeling.
ROR␣ binds to E2F1 through the heptad repeat and marked box domain. During cell cycle progression, a number of coregulators, such as pRb, Sp1, and KAP1, dynamically bind to E2F1 and modulate its activity (36) (37) (38) . We hypothesized that ROR␣ suppresses E2F1 transcription factor activity through a similar mechanism. Coimmunoprecipitation experiments were performed to determine whether ROR␣ binds to E2F1 in epithelial cells. ROR␣ and/or HA-E2F1 vector was cotransfected in HEK293 cells, and the protein complexes were immunoprecipitated by anti-HA antibody. A significant amount of ROR␣ was pulled down in the HA-E2F1-expressing cells but not in the control cells, indicating that ROR␣ binds to E2F1 in HEK293 cells (Fig. 3A) . The interac- tion between ROR␣ and E2F1 was confirmed in MDA-MB 231 cells (Fig. 3B) . We also showed interaction between endogenous ROR␣ and E2F1 in S1 cells by coimmunoprecipitation using E2F1 antibody (Fig. 3C ). In addition, confocal analysis showed that ROR␣ was partially colocalized with E2F1 in the nuclei of MDA-MB 231 cells (data not shown).
ROR␣ exhibits a typical nuclear receptor domain structure consisting of three major domains: a DNA-binding domain (DBD), hinge, and ligand-binding domain (LBD). To understand which domain of ROR␣ is required for E2F1 binding, we performed an in vitro GST pulldown assay. The results showed that the DBD-and-hinge region was able to interact with E2F1 (Fig.  3D ). E2F1 contains a cyclin A-binding domain, helix-loop-helix DNA-binding domain, heptad repeat, marked box, and transactivation domain (Fig. 3E) . To further map the regions in E2F1 involved in ROR␣-E2F1complex formation, in vitro GST pulldown assays were performed with a panel of GST-tagged E2F1 mutants. We found that deletion of the heptad repeat and marked box domain (amino acid 195 to 317) in E2F1 dramatically reduced the ability of E2F1 to bind with ROR␣, indicating that this region is required for ROR␣-E2F1 interaction. The heptad repeat domain mediates the heterodimer formation of E2F1 and DP1. Interestingly, binding of ROR␣ had no effect on formation of E2F1-DP1 dimerization ( Fig. 4A and B) . The results of in vivo and in vitro binding assays indicate that ROR␣ directly interacts with E2F1 to inhibit its activity, but how binding of ROR␣ inhibits E2F1 transcriptional activity remained to be determined.
ROR␣ recruits HDAC1 to E2F1 and reduces its acetylation. It has been shown that covalent modifications, such as acetylation, regulate binding of E2F1 to chromatin and E2F1-dependent tran- scription (40, 41) . To determine whether binding of ROR␣ inhibits E2F1 activity through modulation of the covalent modifications, we checked the acetylation levels on endogenous E2F1 protein in the control and the ROR␣-expressing MDA-MB 231 cells using immunoprecipitation. ROR␣ expression significantly inhibited the lysine acetylation on E2F1 (Fig. 4C) . Since HDACs play a critical role in reducing protein acetylation (46, 47) , we asked whether ROR␣ reduces E2F1 acetylation by recruiting HDACs to the protein complexes. We examined interaction between ROR␣ and endogenous HDAC1 in HEK293 cells using coimmunoprecipitation, and the data showed that HDAC1 bound to ROR␣ (data not shown). To determine whether ROR␣ recruits HDAC1 to E2F1, coimmunoprecipitation experiments were performed in HDAC1-, E2F1-, and/or ROR␣-expressing HEK293 cells. Expression of ROR␣ dramatically enhanced interaction between HDAC1 and E2F1, whereas a weak association between E2F1 and HDAC1 was detected in the absence of ROR␣ (Fig. 4D) .
These results indicate that ROR␣ recruits HDAC1 to E2F1, which, in turn, reduces acetylated lysine levels in E2F1.
To assess whether ROR␣ inhibits E2F1 by recruiting HDAC1 to E2F1, we performed rescue experiments with MDA-MB 231 cells containing the E2F1-Luc reporter construct. Expression of ROR␣ significantly inhibits the luciferase activity in these cells ( Fig. 2C and 4E ). Inhibiting HDAC1 with TSA or shRNA against HDAC1 enhanced E2F1 transcription activity that was suppressed by ROR␣ (Fig. 4E) . Furthermore, silencing HDAC1 partially rescued E2F1 acetylation (Fig. 4F ) and cell proliferation (Fig. 4G) in ROR␣-expressing MDA-MB 231 cells. These data indicate that HDAC1 is required for the inhibitory activity of ROR␣ on E2F1.
ROR␣ reversely correlated with cell proliferation and E2F1 target gene expression in mammary glands. The terminal end bud, a bulbous invasive structure at the tip of growing ducts (48) (49) (50) , has much higher cell proliferation than does the mature duct (19, 20) . This spatial regulation of cell proliferation plays important roles in normal mammary branching morphogenesis. To understand the roles of the ROR␣-E2F1 axis in spatial regulation of cell proliferation in mammary tissue, we analyzed the expression of ROR␣ and E2F1-targeted genes in a published microarray data set generated from mouse terminal end bud and mature duct tissues (51) . ROR␣ mRNA levels were significantly reduced in the terminal end buds compared to duct glands, while expression of E2F1-targeted genes was significantly upregulated in the terminal end bulb (Fig. 5A to C) . Immunohistochemistry analysis confirmed that ROR␣ expression was reduced in terminal end buds compared to ductal epithelial cells in mouse mammary glands. There were more Ki67-positive cells in the terminal end buds than in ducts (Fig. 5D) , which is consistent with the previous finding that cells in terminal end buds are highly proliferative (19, 20) . A reverse correlation of ROR␣ with cell proliferation and expression of the E2F1 target genes in terminal end buds and ductal epithelial cells suggests potential roles for ROR␣ in regulating mammary branching morphogenesis.
Next, we performed mammary gland transplant experiments to examine the function of ROR␣ in spatial regulation of cell proliferation during branching morphogenesis. Primary mammary organoids were isolated from FVB mice and infected with lentivirus containing control shRNA or shROR␣. The infected mammary gland organoids were transplanted into 3-week-old FVB mice with cleared fat pads. Five weeks following transplantation, the transplanted mammary glands were taken out for immunohistochemistry analysis and whole-mount staining. Ki67 staining showed that knockdown of ROR␣ significantly enhanced cell proliferation in the ductal epithelial cells (Fig. 5E and F) but had little effect on cell proliferation in the terminal end buds (Fig. 5E and  F) . We also found that ROR␣-silenced mammary glands had increased side branching ( Fig. 5G and H) , suggesting that ROR␣-induced growth arrest is important for normal mammary branch morphogenesis.
DISCUSSION
A function for ROR␣ in regulating cell proliferation has been reported previously (7, 25) , but how ROR␣ inhibits cell proliferation in normal tissue development and disease progression remains unclear. In the present study, we found that ROR␣ bound to E2F1 as a cofactor and inhibited E2F1 activity by recruiting HDAC1 to the ROR␣-E2F1 complex. These findings identify a noncanonical pathway of ROR␣ to suppress E2F1-targeted gene and cell cycle progression.
Cross talk between E2F and other transcription factors has been reported previously (52) (53) (54) (55) (56) . For instance, interaction between aryl hydrocarbon receptor (AHR) and E2F1 has been detected in mouse hepatoma cells, and binding of AHR suppresses E2F1-mediated apoptosis by modulating E2F1 transcriptional activity (54, 55, 57) . We showed that binding of ROR␣ reduced acetylation levels on E2F1 and inhibits its DNA binding activity. Lysine acetylation is an important posttranslational modification that regulates E2F1 activity. It has been reported that lysine residues 117, 120, and 125 on E2F1 are acetylated by the acetyltransferase complex CBP/p/CAF and that the acetyl group can be removed by HDAC proteins. Acetylation of E2F1 enhances its DNA binding ability and increases protein stability (41) . It has been shown that Rb, mSin3B, Ebp1, and RbAp48 recruit class I HDACs (HDAC 1, HDAC2, and HDAC3) to E2Fs and modulate E2F target gene expression (58) (59) (60) (61) . Our data showed that ROR␣ enhanced interaction between E2F1 and HDAC1; reducing HDAC1 expression or inhibiting its activity rescued E2F1 activity suppressed by ROR␣. However, microarray data showed that the majority, but not all, of E2F1-targeted genes are inhibited by ROR␣, suggesting that some E2F1-targeted gene may be dominantly regulated by other transcription factors or epigenetically silenced. These results identify a novel pathway by which nuclear receptor modulates E2F1 transcriptional activity.
Cell proliferation is tightly regulated during branching morphogenesis, a fundamental developmental process that shapes the formation of mammary glands (21, 22) . Steroid hormones, local growth factors, and their receptors play important roles in mammary gland branching morphogenesis. For example, deletion of insulin-like growth factor I receptor in mammary epithelial cells inhibits cell proliferation in terminal end buds and impairs mammary branching morphogenesis in mice (19) . We found that ROR␣ expression was reversely correlated with cell proliferation in terminal end bud and mammary ducts, suggesting ROR␣ as the inhibitor of cell proliferation during branch morphogenesis. In fact, knockdown of ROR␣ increased E2F1 target gene expression and cell proliferation in the mammary ducts and enhanced side branching in the transplanted mammary gland. Therefore, increased ROR␣ expression in mammary ducts is crucial to maintain the ductal structure by inhibiting cell proliferation (Fig. 6 ). In addition, it has been reported that Wnt signaling has been identified as a downstream target of progesterone to induce side-branch morphogenesis (62, 63) . ROR␣ has been shown to bind to ␤-catenin and inhibits the Wnt pathway during colon cancer development (7). Thus, the Wnt/␤-catenin pathway is also a potential target of ROR␣ to regulate branching morphogenesis.
Uncontrolled cell proliferation is a hallmark of cancer development and progression, and dysregulation of the pRB/E2F pathway plays a critical role in the enhanced cell proliferation in cancer tissue. Mutation or deletion of pRB has been detected in many cancers (64) (65) (66) (67) . However, it has been shown that in human breast cancer patients, only about 20 to 30% of breast tumors are pRB deficient and less than 10% of tumors show inactivated or mutated pRB (64, 65) . These results suggest that other proteins or pathways inhibit expression or activation of E2F1 during breast cancer development. Our previous study shows that 70% of human breast cancers have reduced ROR␣ expression (25) . Ectopic expression of ROR␣ in breast cancer cells reduces cell proliferation and inhibits and tumor growth. Thus, aberrant activation of the E2F1 pathway and cell cycle progression in breast cancer are at least partially due to reduced ROR␣ expression. Further investigation of the connection of ROR␣ with E2F1 activation and cell proliferation in breast cancer tissue may lead to discovery of a potential pathway to inhibit breast cancer progression.
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